Related coverage linked through entity extraction aliases.
Jun 24, 2026
A phase 3 trial shows that the oral drug enlicitide reduces LDL cholesterol by 60% compared to placebo, according to results published in the New England Journal of Medicine. Sponsored by Merck & Co., the trial involved 2,909 participants with atherosclerosis or at risk. If approved, enlicitide could help lower heart attack and stroke risk.
Jun 23, 2026
The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.
Jun 19, 2026
Portal Biotechnologies closes $9M funding round to expand cell engineering platform for drug discovery and cell therapy. Navikenz raises $7.5M seed round to scale AI transformation services focused on life sciences and pharmaceuticals.
Jun 13, 2026
Teva Pharmaceuticals and Sanofi reported positive Phase 2b long-term extension results for duvakitug, a TL1A-targeting monoclonal antibody, showing durable efficacy over 44 weeks in ulcerative colitis and Crohn's disease patients. UC patients achieved up to 58% clinical remission and CD patients up to 55% endoscopic response at the higher dose.
Jun 11, 2026
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
Jun 09, 2026
Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.
Jun 09, 2026
The FDA is receiving extensive industry feedback on three regulatory initiatives: draft guidance for using new approach methodologies to reduce animal testing, the Commissioner's National Priority Voucher pilot program, and a proposed rule to update the National Drug Code format. Stakeholders are urging revisions to the NAMs guidance, improvements to the CNPV program, and timely finalization of the NDC rule to avoid disruptions.
Jun 08, 2026
Major biotech investment and M&A activity marked early 2026, including a significant stake purchase in TG Therapeutics and multiple high-value acquisitions within the RTW Biotech Opportunities portfolio. The sector showed improving capital markets and strategic deal interest following the JPMorgan Healthcare Conference.
Jun 06, 2026
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Jun 05, 2026
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
May 26, 2026
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.
May 22, 2026
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
May 19, 2026
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
May 12, 2026
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
May 07, 2026
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
Apr 27, 2026
The FDA approved Keytruda and Keytruda Qlex with paclitaxel, with or without bevacizumab, for PD-L1-positive platinum-resistant ovarian-related cancers. The Phase III KEYNOTE-B96 trial showed improved progression-free and overall survival versus placebo.
Apr 26, 2026
Merck received FDA approval in early February 2026 for KEYTRUDA and KEYTRUDA QLEX in PD-L1-positive platinum-resistant ovarian cancer. The decision marks the first approval of a PD-1 inhibitor regimen for this setting.
Apr 23, 2026
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
Apr 23, 2026
MSD signed a Google Cloud agreement worth up to $1 billion and entered an AI-focused R&D collaboration with Mayo Clinic. The deals expand AI use in drug discovery, development and broader operations.
Apr 22, 2026
Deutsche Bank upgraded Merck to Buy and raised its price target to $150 from $115, citing a clear path beyond Keytruda’s patent expiration. Merck meanwhile forecast 2026 revenue of $65.5 billion to $67.0 billion and said it faces a $2.5 billion headwind this year.
